Skip to content
1st Counsel – Lifestyle
Author:
Alebund Pharmaceuticals
Alebund Pharmaceuticals Announces 2026 Interim Results
August 26, 2026
Alebund’s AP301 NDA Accepted for Review by China’s NMPA
August 7, 2026
Alebund Pharmaceuticals Announces First Participant Randomized and Dosed in Global Phase IIb Multi-Regional Clinical Trial of AP306 for Hyperphosphatemia
July 21, 2026
Alebund Pharmaceuticals (09637.HK) Debuts on the HKEx Main Board
June 29, 2026